Key multiple sclerosis companies such as Sanofi, Immunic, InnoCare Pharma, Tiziana Life Sciences, Biogen, J-Pharma, Bristol-Myers Squibb, Polpharma Biologics, Repertoire Immune Medicines, Nervgen ...

The multiple sclerosis (MS) disease-modifying therapy (DMT) market across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan) is poised to grow at a compound annual ...

DelveInsight’s multiple sclerosis competitive report depicts a robust space with 60+ active players working to develop 75+ pipeline multiple sclerosis treatments. Key multiple sclerosis companies such ...

Sanofi eyes filings for multiple sclerosis therapy tolebrutinib, although two of three phase 3 trials miss their primary endpoints.

Two veteran biotech investors have reunited to form a new venture capital firm focusing on autoimmune diseases. Steven St. | ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Denali Therapeutics remains an intriguing clinical-stage biotech focused on neurodegenerative and lysosomal storage diseases.

The quest to mitigate disability progression in multiple sclerosis (MS) has long been hindered by our limited understanding ...

Revolution Medicines projected its cash and equivalents of $2.1 billion would last into the second half of 2027. With new funding from Royalty Pharma, the biotech has withdrawn that runway end date.

Teva Pharmaceutical Industries Limited’s TEVA shares have risen 21.6% in three months. Over the past few quarters, Teva has ...

Sanofi’s SNY stock has been trading below its 200-day and 50-day moving averages since early June. On June 23, the stock’s closing price of $48.18 was below its 50-day moving average of $50.32 and the ...

AbbVie has agreed to buy Capstan Therapeutics for up to $2.1 billion, expanding its pipeline with a potential first-in-class ...